Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOKYO.L Regulatory News (OKYO)

  • There is currently no data for OKYO

Disposal

9 Jul 2010 11:44

For Immediate Release: 9 July 2010

EMERGING METALS LIMITED ("EML" or the "Company") Disposal

The Company is pleased to announce that it has entered into an agreement to dispose of its entire holding of 368,721 shares in Extract Resources Limited ("EXT Shares") to Nippon Uranium Resources (Australia) Proprietary Limited at a price of A$7.00 in cash per EXT Share. The gross proceeds of the sale will be A$2,581,047, approximately £1.48 million, which will be available for EML to apply in accordance with its investing policy approved by shareholders on 16 April. The sale is conditional on certain Australian regulatory approvals and completion is expected to be no later than 17 August 2010.

Extract Resources Limited ("EXT") is an ASX listed uranium exploration and development company with significant uranium assets in Namibia, namely the Husab uranium project comprising the Rossing South, Ida Dome and Hildenhof deposits and the EXT Shares represent approximately 0.15 per cent. of EXT's issued share capital.

ENQUIRIES:Emerging Metals Religare Capital Fox-Davies Capital GTH Communications Limited Markets Limited Daniel Fox-Davies Denham Eke Peter Toby Hall Trevelyan-Clark +44 (0) 20 7936 +44 (0) 1624 5200 Christian Pickel 639396 Emily Staples +44 (0) 20 3103 3900 +44 (0) 20 7444 0800

vendor
Date   Source Headline
7th Sep 20221:30 pmRNSResult of AGM
30th Aug 20227:00 amRNSQ4 '22 IND planned followed by P2 with AmbioPharm
19th Aug 20227:00 amRNSNotice of AGM
18th Aug 20222:06 pmRNSSecond Price Monitoring Extn
18th Aug 20222:00 pmRNSPrice Monitoring Extension
16th Aug 20227:00 amRNSAnnual Financial Report
9th Jun 20227:08 amRNSDirector/PDMR Shareholding
20th May 20227:00 amRNSDirector/PDMR Shareholding
19th May 20224:01 pmRNSClosing of Offering
18th May 202210:10 amRNSDirector/PDMR Shareholding
17th May 20227:00 amRNSOKYO Announces Pricing of IPO of ADSs in the U.S.
27th Apr 20227:00 amRNSUpcoming Presentations at Ophthalmic Conference
7th Mar 20227:00 amRNSAdditional Listing
23rd Feb 20227:00 amRNSPatent issued: to treat ocular neuropathic pain
21st Feb 20225:00 pmRNSCLN Conversion, exercise of Warrants, equity issue
15th Feb 20227:00 amRNSSuccessful Pre-IND Meeting with the FDA on OK-101
1st Feb 20227:00 amRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSDirector/PDMR Shareholding
26th Jan 20222:05 pmRNSSecond Price Monitoring Extn
26th Jan 20222:00 pmRNSPrice Monitoring Extension
26th Jan 20227:00 amRNSHalf-year Report
14th Dec 20217:00 amRNSU.S. Patent issued for use of OK-101 to treat DED
13th Dec 20217:00 amRNSOK-101:Anti-inflammatory & Pain-Reducing Potential
6th Dec 20217:00 amRNSIND filing Q3 2022 and Phase 2 initiation Q4 2022
1st Dec 20217:00 amRNSDirectorate Change
19th Oct 20214:41 pmRNSSecond Price Monitoring Extn
19th Oct 20214:35 pmRNSPrice Monitoring Extension
19th Oct 20212:05 pmRNSSecond Price Monitoring Extn
19th Oct 20212:00 pmRNSPrice Monitoring Extension
27th Sep 202112:06 pmRNSResult of AGM
9th Sep 20217:00 amRNSNotice of AGM
1st Sep 20217:00 amRNSDirector/PDMR Shareholding
2nd Aug 202111:32 amRNSAnnual Financial Report
29th Jun 20217:00 amRNSResearch Update
17th Jun 20213:58 pmRNSDirectorate Change
12th May 20217:00 amRNSHolding(s) in Company
7th May 202110:07 amRNSAdditional Listing
5th May 202111:53 amRNSPublication of a Prospectus
28th Apr 20217:00 amRNSPositive Data in an Animal Model using OK-201
29th Mar 20217:00 amRNSAppointment of Chief Scientific Officer
3rd Mar 20217:00 amRNSIssue of Equity
1st Mar 20217:00 amRNSIssue of Equity
23rd Feb 20217:00 amRNSPatent for treating Ocular Pain and Inflammation
19th Jan 20217:00 amRNSFiling patent application for the use of Chemerin
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:37 pmRNSPrice Monitoring Extension
14th Jan 20212:05 pmRNSSecond Price Monitoring Extn
14th Jan 20212:00 pmRNSPrice Monitoring Extension
7th Jan 20217:00 amRNSDirectorate Change
30th Nov 20207:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.